Syra Madad, DHSC, MSC; and Vikram Mukherjee, MD


10 Key Pillars to an Effective Ebola Response

EVD outbreaks this year serve as a reminder of the virus’ severity and the importance of having a containment strategy in place.

Kristin L. Feick, PHARMD, BCPS


Oral Therapeutic Options to Prevent Disease Progression From COVID-19 in an Ambulatory Setting

As the number of COVID-19 cases continues to rise, oral treatment options for at-home use are in demand to provide early intervention and reduce the progression to severe disease, hospitalization, and death.

Michael Trisler, PharmD, MPH, BCIDP


Daptomycin as Frontline Therapy for MRSA Bacteremia: Has the Time Come?

Findings increasingly suggest the mortality risk may be reduced by initiating daptomycin within 3 days of infection.

Cynthia Miller, MD, MPH


The Tripledemic as a Precursor to Stakeholder Alignment under the Quintuple Aim

Infectious disease outbreaks will continue to increase and trying to find strategies to ensure providers are cared for to prevent burnout and shortage staffing is essential if another pandemic arises.

Olivia G. Funk, PharmD


The Next Generation of COVID-19 Vaccines and Boosters

Will there be an answer to keep the continuously evolving virus at bay? Are seasonal combination vaccines the wave of the future?

Dhruv P. Patel, MD


Revisiting Old Foes: Updates on HSV

Herpes simplex viruses are chronic infections that underscore racial and ethnic disparities and are afflicting adolescents in increasing numbers.

Yosef Nissim PharmD, BCIDP


CDC Updates Pneumococcal Conjugate Vaccine Recommendations

The federal agency recommends using either PCV13 or PCV15 as part of a 4-dose series for pediatric patients between the ages of 2-59 months.

Karisma Patel, PharmD, BCPPS, BCIDP


Antimicrobial Stewardship: How to Extend a Solid Handshake

In the latest column from SIDP, handshake stewardship prioritizes face-to-face communication between frontline providers to enable feedback to assess the appropriateness of prescribed antimicrobials.

Megan Chatowsky, PharmD Candidate


Secnidazole Offers Hope as Option for Treating Trichomoniasis in Women

This nitroimidazole antibiotic is shown to be efficacious for this condition.

Kerry LaPlante, PharmD, FCCP, FIDSA, FIDP


Antibiotic Stewardship in Outpatient Care

Although there are challenges for clinical and infectious disease pharmacists when trying to apply this concept, here are some considerations and strategies to employ stewardship in this setting.

Jason M. Broderick


MRNA COVID-19 Vaccines and Male Fertility

According to a small study, the Moderna and Pfizer COVID-19 vaccines do not impact male fertility.

Grace McComsey, MD, FIDSA


Multidisciplinary Perspectives on HIV Treatment

A multidisciplinary panel concludes a discussion on best practices for managing patients with HIV in various healthcare settings and overcoming social health disparities.

Jason Gallagher, PharmD, FCCP, FIDP, FIDSA, BCPS


COVID-19 Booster Shots and the Future

Key opinion leaders provide some advice for the public regarding COVID-19 booster shots and look to the future of the pandemic.

Geraldine A. Finlay, MD


Identifying Disparities in Sepsis Diagnosis for Unbiased Care

Risk of inaccuracy with pulse oximeters and clinician knowledge gaps in people of color may affect sepsis evaluations and impact treatment plans.

George Loukatos, MD


Future Directions for Managing COVID-19 and Influenza

George Loukatos, MD, shares clinical pearls for the management of the SARS-CoV-2 and influenza viruses.

Subramanya Shyam Ganti, MD, MBBS


Challenges in the Management of Mycobacterium abscessus Complex

This pathogen is the third most frequently isolated nontuberculous mycobacteria seen in the United States. Here is a review of how it presents and treatment options.

Jennifer Cocohoba, PharmD


Contemporary Issues on the Treatment of Women Living with HIV in the US

The increasing presence of multiple non-AIDS comorbidities in women and others living with HIV challenges clinicians to steer away from the approach of optimizing individual chronic conditions but to think more holistically.

Paul Monach, MD, PhD


From Pandemic to Endemic

A research agenda focusing on breakthrough infections, reinfections, severity, and sequelae is needed to inform clinical practice when COVID-19 emphasis shifts from eradication to living with the disease.



So You Made the Decision to Implement Vancomycin AUC Dosing. Now What?

Since the vancomycin guideline update, institutional leaders have been faced with the challenge of implementing and monitoring AUC-guided dosing.

Jessica Malaty Rivera, MS


Why Aren’t We Better Protecting Our Youngest Children Against Infections?

Vaccinations and mitigations for COVID-19 and other respiratory viruses have not been made a priority for young children. Let’s change this before the next big surge hits.

Nisha Patel, PharmD, BCPS


To Prophylax or not to Prophylax: Preventing CDI

Clinicians look at optimal approaches for trying to avoid Clostridioides difficile infection (CDI).

Alison L. Blackman, PharmD, BCIDP


So You Made the Decision to Implement Vancomycin AUC Dosing. Now What?

Since the vancomycin guideline update, institutional leaders have been faced with the challenge of implementing and monitoring AUC-guided dosing.

Brandon Dionne, PharmD, BCPS-AQ ID, BCIDP, AAHIVP


I Kidney Not: Antibiotic Dosing Strategies in Intermittent Hemodialysis

In the latest article from SIDP, here is a look at the use of various intravenous (IV) antimicrobial therapies to address infections in these patients.

Jesse S. Veisblatt, MD


Bad Bugs, New Drugs: A Discussion of Selected New Therapeutics From IDWeek 2022

Cefepimetaniborbactam may represent a safe and effective carbapenemsparing agent in cUTI and AP, whereas ridinilazole may play an important role in treating CDI.

© 2023 MJH Life Sciences

All rights reserved.